HHV-8/KSHV-negative and CD20-positive primary effusion lymphoma successfully treated by pleural drainage followed by chemotherapy containing rituximab

Yasushi Terasaki, Hirokazu Okumura, Katsuhiko Saito, Yasuharu Sato, Tadashi Yoshino, Ryo Ichonohasama, Youichi Ishida

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The present patient was diagnosed as having human herpes virus-8 (HHV-8)/ Kaposi sarcoma herpes virus (KSHV)-negative and CD20-positive primary effusion lymphoma (PEL) of the right-sided pleural effusion. After pleural drainage, malignant cells disappeared spontaneously in a small amount of the remaining pleural effusion without chemotherapy. The patient was treated with six cycles of chemotherapy consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. He has been in complete remission for more than 22 months. It is suggested that effusion drainage followed by chemotherapy containing rituximab is a potential treatment strategy for patients with HHV-8/KSHV-negative and CD20-positive PEL.

Original languageEnglish
Pages (from-to)2175-2178
Number of pages4
JournalInternal Medicine
Volume47
Issue number24
DOIs
Publication statusPublished - 2008

Keywords

  • Pleural effusion drainage
  • Primary effusion lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'HHV-8/KSHV-negative and CD20-positive primary effusion lymphoma successfully treated by pleural drainage followed by chemotherapy containing rituximab'. Together they form a unique fingerprint.

  • Cite this